Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
209lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
4 lessons
9mResearchAdvanced
Retatrutide's FDA Watch Tightens After the Latest Obesity Trial Results
Retatrutide keeps stacking strong data, and the latest trial update sharpens the path toward an FDA submission. The bigger story is not just weight loss. It is how the triple-agonist profile may change what obesity medicine expects from a next-wave therapy.
9mPeptidesIntermediate
What Real-World GLP-1 Data Actually Tells Us About Safety and Results
Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mPeptidesIntermediate
GLP-1s and Breast Cancer Risk: What the New Signal Means
GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
8mResearchAdvanced
GLP-1s and Macular Degeneration: What the Eye Studies Say
GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.
Also available at /blog for legacy links.